SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
Takeda’s AI-crafted psoriasis pill succeeds in late-stage studies
Dec 18 (Reuters) – Japan’s Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin…